During the last session, Checkpoint Therapeutics Inc (NASDAQ:CKPT)’s traded shares were 1.65 million, with the beta value of the company hitting 1.30. At the end of the trading day, the stock’s price was $3.44, reflecting an intraday loss of -4.97% or -$0.18. The 52-week high for the CKPT share is $3.97, that puts it down -15.41 from that peak though still a striking 60.47% gain since the share price plummeted to a 52-week low of $1.36. The company’s market capitalization is $154.86M, and the average intraday trading volume over the past 10 days was 1.62 million shares, and the average trade volume was 553.56K shares over the past three months.
Checkpoint Therapeutics Inc (CKPT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CKPT has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.15.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Checkpoint Therapeutics Inc (NASDAQ:CKPT) trade information
The stock plummet -4.97% in intraday trading to $3.44, hitting a weekly high. The stock’s 5-day price performance is 0.00%, and it has moved by 53.57% in 30 days. Based on these gigs, the overall price performance for the year is 84.95%. The short interest in Checkpoint Therapeutics Inc (NASDAQ:CKPT) is 4.61 million shares and it means that shorts have 10.39 day(s) to cover.
Checkpoint Therapeutics Inc (CKPT) estimates and forecasts
Statistics show that Checkpoint Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Checkpoint Therapeutics Inc (CKPT) shares have gone up 132.43% during the last six months, with a year-to-date growth rate more than the industry average at 74.45% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 48.30% this quarter and then jump 85.50% in the quarter after that. In the rating firms’ projections, revenue will decrease -70.90% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 10k as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 10k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 31k and 6k respectively. In this case, analysts expect current quarter sales to shrink by -67.70% and then jump by 66.70% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 26.32%. While earnings are projected to return 75.29% in 2024.
CKPT Dividends
Checkpoint Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Checkpoint Therapeutics Inc (NASDAQ:CKPT)’s Major holders
Checkpoint Therapeutics Inc insiders own 15.52% of total outstanding shares while institutional holders control 13.68%, with the float percentage being 16.19%.
